Please assess the completion status of the following clinical trial:

Trial Title: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* ≥ 2 years and ≤ 21 years of age at the time of study entry~* Scheduled to receive chemotherapy for:~* Newly diagnosed:~* Non-rhabdo soft tissue sarcomas, scheduled to receive chemotherapy, as well as intermediate or high-risk rhabdomyosarcoma, any stage osteosarcoma and any stage Ewing's sarcoma~* Intermediate or high-risk neuroblastoma~* Wilms' tumor (Stage III/IV)~* Hepatoblastoma (Stage III/IV)~* Germ cell tumors (Stage III/IV)~* Brain tumors, including medulloblastoma, PNET and ependymomas~* AML~* Relapsed/recurrent disease (any patient)~* Able to register and randomize within 28 days of starting chemotherapy (registration /randomization and start of study agent may occur at anytime up to and including Day 28 after the initiation of chemotherapy)~EXCLUSION CRITERIA:~* ≥ 29 days after starting chemotherapy~* Documented history of unintended weight loss ≥ 5% presumed secondary to cancer within 3 months of study entry~* Currently taking cyproheptadine HCl (or have taken cyproheptadine HCl within 3 weeks of study registration)~* History of anorexia nervosa or bulimia~* Taking other appetite-stimulating medications, i.e. dronabinol (Marinol) during the past three weeks.~* Initiation of other appetite enhancing agents, including steroids prescribed for the intent of weight gain, i.e. Megace. Note: Other forms of nutrition therapies, e.g. appetite-stimulating medications, TPN or enteral tube feedings are not allowed during this study.~* Children receiving steroids for \>7 days as part of their cancer treatment regimen are excluded from participation. However, intermittent steroid use in an antiemetic regimen is allowed during the study~* Receiving monoamine oxidase (MAO) inhibitors, procarbazine, fluoxetine (Prozac), or paroxetine (Paxil)~* Diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease, or GI/GU obstruction~* Allergy to cyproheptadine HCl~* Females of childbearing age must not be pregnant.~* Female patients who are lactating must agree to stop breast-feeding.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm I cyproheptadine hydrochloride (Type: EXPERIMENTAL): Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
- Arm II placebo (Type: PLACEBO_COMPARATOR): Patients receive an oral placebo twice daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).